AHSG and neoplasm: As for CRC, serum alpha-2-HS-glycoprotein inhibits tumor progression by blocking transforming growth factor-β1 (TGF-β1) binding to cell surface receptors, suppressing TGF-βsignal transduction, and inhibiting TGF-β-induced epithelial-mesenchymal transition [55].